Skip to main content

Palvella Therapeutics, Inc. (PVLA) Stock

Palvella Therapeutics, Inc. Stock Details, Movements and Public Alerts

Stock Details

Palvella Therapeutics, Inc. (PVLA), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NCM.Currently, the stock is trading at $122.06. Over the past 52 weeks, it has ranged between $18.23 and $151.18. This places the current price at 80.7% of its 52-week high and 569.7% above its 52-week low. Recent trading volume was recorded at 520,765. The 14-day Relative Strength Index (RSI) stands at 74.55, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $91.84 by 32.91%. Similarly, it is above its 200-day moving average of $61.74 by 97.70%. The MACD histogram is 3.52, indicating bullish momentum (MACD Line: 1.16, Signal Line: -2.35).

52-Week Range

$151.18 - $18.23

-19.26% from high · +569.74% from low

Avg Daily Volume

350,508

20-day average

100-day avg: 258,575

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-30.93

Price to Book

34.98

EPS (TTM)

-$2.92

Q:How is PVLA valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is PVLA's risk profile compared to the market?
Risk profile data is not available for this stock.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

Return on Equity

-301.19%

Return on Assets

-47.54%

Q:How profitable and efficient is PVLA's business model?
Profitability metrics are not available for this stock.
Q:What are PVLA's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$1.7B

Shares Outstanding

14.23M

Book Value/Share

$3.49

Asset Type

EQUITY

Q:What is PVLA's market capitalization and position?
Palvella Therapeutics, Inc. has a market capitalization of $1.7B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 14.23M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does PVLA's price compare to its book value?
Palvella Therapeutics, Inc.'s book value per share is $3.49, while the current stock price is $122.06, resulting in a price-to-book (P/B) ratio of 34.98. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$224.27

83.73% upside potential

Analyst Recommendations

Strong Buy

0

Buy

12

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for PVLA?
12 analysts cover PVLA with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $224.27 implies 83.7% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on PVLA?
Current analyst recommendations:012 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 15, 2026, 02:05 AM

Technical Indicators

RSI (14-day)

74.55

Overbought

50-Day Moving Average

$91.84

32.91% above MA-50

200-Day Moving Average

$61.74

97.70% above MA-200

MACD Line

1.16

MACD Signal

-2.35

MACD Histogram

3.52

Bullish

Q:What does PVLA's RSI value tell investors?
The RSI (Relative Strength Index) for PVLA is currently 74.55, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret PVLA's MACD and moving average crossovers?
MACD analysis shows the MACD line at 1.16 above the signal line at -2.35, with histogram at 3.52. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($91.84) is above the 200-day MA ($61.74), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Feb 25, 2026, 09:00 PM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for PVLA and get notified when the price changes.

Stay Ahead of the Market with Palvella Therapeutics, Inc. Alerts

Set up price alerts for Palvella Therapeutics, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.